Select Page

Psilocybin Reduces Distress in Those Who Suffered Childhood Trauma

Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

A Canadian study published in the “Journal of Psychoactive Drugs has revealed that psilocybin, the main hallucinogenic agent in magic mushrooms, may reduce psychological distress in individuals with childhood trauma. The researchers found a possible association between magic mushroom use and declines in psychological distress, especially among people with adverse childhood experiences (ACE) after exploring the relationship between psychological distress and psilocybin use.

Like several other classic psychedelics, psilocybin has been subject to increased attention in recent years, thanks to anecdotal and scientific claims of its medical efficacy. Previous research efforts have found that psilocybin may be effective at treating debilitating psychological illnesses and reducing symptoms such as suicide ideation.

The recent Canadian study delved deeper into the connection between psychedelic use and adverse childhood experiences including neglect, exposure to violence and abuse, which regularly leave long-lasting mental scars.

Simon Fraser University assistant professor of health sciences and study author Kiffer G. Card says the research team was especially interested in whether the widely accessible psilocybin could benefit people suffering from the long-term effects of ACEs. Card and his team used email and online platforms such as Reddit, Instagram and Facebook to recruit 1,249 study participants of diverse backgrounds, ethnicities and sexual orientations; participants had an average age of 39.8 years.

The participants provided data on key demographics such as gender, age, income, education, disability status, ethnicity and sexual orientation as well as their history of psilocybin use. The researchers also asked the participants to fill out the Adverse Childhood Experiences  (ACE) Questionnaire, which assesses childhood traumas such as exposure to substance abuse, neglect, domestic violence and abuse. Participants also filled out the Psychological Distress Scale (K6), which measures the frequency of distressing psychological symptoms such as hopelessness, nervousness, restlessness, worthlessness and depression within the past month.

The researchers found that participants who used psilocybin within the past three months had reduced levels of psychological distress compared to participants who didn’t use the psychedelic, indicating that recent magic mushroom use may be able to lower symptoms of psychedelic distress. Interestingly, psilocybin use seemed to produce a pronounced beneficial effect on people with higher ACE levels.

Most participants reported using psilocybin at least once in their lives, and the majority said they used the psychedelic to deal with emotional and mental-health challenges and as a self-help tool.

Card noted that while the study was only observational, it adds to the literature connecting psilocybin use with mental-health benefits, particularly in people who were exposed to severe childhood distress.

The psychedelic drug candidates that enterprises such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are developing could help in effectively treating specific kinds of mental-health issues that currently have few treatment options.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

This post was originally published by our media partner here.